Inhibrx Biosciences, Inc.
Inhibrx Biosciences, Inc. (INBX) Revenue
Annual & quarterly revenue history · segment & region breakdown
INBX · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsInhibrx Biosciences, Inc. trailing twelve-month (TTM) revenue is $0.00B, an increase of 550.00% year-over-year from $0.00B in FY2025.
Revenue trend
2025 – 2016 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.00B | +$0.00B | +550.00% |
| 2024-12-31 | $0.00B | -$0.00B | -88.89% |
| 2023-12-31 | $0.00B | -$0.00B | -17.88% |
| 2022-12-31 | $0.00B | -$0.00B | -69.24% |
| 2021-12-31 | $0.01B | -$0.01B | -44.37% |
| 2020-12-31 | $0.01B | +$0.00B | +40.86% |
| 2019-12-31 | $0.01B | +$0.00B | +21.24% |
| 2018-12-31 | $0.01B | -$0.00B | -5.66% |
| 2017-12-31 | $0.01B | +$0.00B | +19.24% |
| 2016-12-31 | $0.01B | — | — |
Compare revenue vs peers
BiotechnologyCompare INBX revenue against listed peers. Click any row to open that company's revenue tab.
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Inhibrx Biosciences, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Inhibrx Biosciences, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Inhibrx Biosciences, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
INBX revenue · 4 questionsINBX's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 550.00% year-over-year from $0.00B in FY2025.
▸ Source: FMP · Inhibrx Biosciences, Inc. SEC filings · GAAP · Inhibrx Biosciences, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026